Reply  by Macdonald, Peter
failure. We would be happy to collaborate with Dr. Stein to study
“erratic sinus rhythm” with a specific research software, because the
analogic tape of the ambulatory electrocardiograms of our patients
is still available. However, from a practical standpoint, we consider
that an important issue of our article is that our results were
obtained with a commercially available Holter monitoring system,
and with demonstration that SDNN, a simple and reproducible
measurement of HRV, is probably the most powerful for risk
stratification. These findings may have more direct implications for
identifying patients at risk and may guide subsequent investiga-
tions and therapy, either on an individual basis or as part of a
controlled clinical trial.
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Carvedilol in Class IV Heart Failure
Macdonald et al. (1) have reported favorably on the use of
carvedilol in patients with New York Heart Association functional
class IV heart failure. However, no mortality figures were stated.
Table 3, “Nonfatal Adverse Events,” indicates that 27 of 63
patients in functional class IV experienced adverse events, most
commonly worsening heart failure. But no information on the
number of deaths in the 63 patients is reported. On page 933,
“Actuarial Survival,” the statement is made that “the 1-year
mortality of 16 6 5% in this patient group treated with carvedilol
compares favorably with the mortality reported for similar patient
groups in other studies.” However, patients in functional class IV
heart failure with certain unfavorable characteristics were excluded.
The following were the exclusion criteria: cardiogenic shock,
intractable pulmonary or systemic edema, heart failure requiring
intravenous inotropic or mechanical support, bradycardia with
heart rate ,50 beats/min, systemic hypotension with blood pres-
sure ,80/50 mm Hg or chronic air flow limitation with evidence
of $20% reversibility in airway obstruction in response to inhaled
salbutamol. It would seem reasonable to expect that with these very
sick patients excluded from the treatment group, the mortality
figures in the remainder receiving carvedilol would be clearly
favorable in comparison to any control group, if carvedilol were
indeed beneficial.
Because adverse events with carvedilol therapy usually occur
early in the treatment course, it would be important to know not
only how many of the treated patients in functional class IV died,
but also the duration of their treatment before death. One would
anticipate that the deaths occurred early.
Additional data on the survival of patients in functional class IV
heart failure treated with carvedilol are clearly needed.
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We thank Dr. Hoffman for his comments. As stated in our report
(1), the actuarial survival rate for patients in New York Heart
Association functional class IV heart failure at one year was 84%
and the one-year mortality rate was 16%. Overall, 10 patients in
functional class IV died within the first year after commencement
of carvedilol. As shown in Figure 1 (page 926), the deaths occurred
throughout the year, with no apparent clustering at the time of
initiation or titration of carvedilol. Causes of death were judged to
be progressive heart failure in five patients and sudden cardiac
death in five patients. All five patients who died suddenly were
taking carvedilol at the time of their death and had been treated for
6, 74, 96, 127 and 203 days, respectively. Deaths from progressive
heart failure occurred at days 41, 46, 142, 153 and 259. Carvedilol
was withdrawn before death in all five patients who subsequently
died of progressive heart failure. The reason for withdrawal in all
five patients was worsening heart failure, and the period between
carvedilol withdrawal and death ranged from 23 to 228 days.
We recognize that not all patients in functional class IV heart
failure referred to our institution were challenged with carvedilol;
however, we believe our patients are comparable to those in class
IV included in the other studies that we have cited. For instance,
in the CONSENSUS Study (26) in which the 1-year mortality
rate for enalapril was ;40%, all patients had to be stable on
medical therapy for 2 weeks before trial entry. Patients on
intravenous inotropic therapy and mechanical support were ex-
cluded. Similarly, in the study of Lee and Packer (19), only
patients with stable chronic functional class IV heart failure were
included. The one-year mortality rate in this study for patients
receiving angiotensin-converting enzyme inhibitors was ;50%.
As stated in the Discussion of our report, we can only speculate
on the impact of carvedilol on survival; however, we believe that a
one-year mortality rate of only 16% compares favorably with
historic reports such as those cited. The recently published Cardiac
Insufficiency Bisoprolol Study (CIBIS-II) (2) provides the stron-
gest evidence to date that the beneficial effects of beta-blockers in
heart failure extend to patients who are in functional class IV at
baseline. Seventeen percent of 2,647 patients entered into
CIBIS-II were in functional class IV at baseline. Active treatment
with bisoprolol reduced mortality by 34% as compared with
placebo, with no significant difference between class III and class
IV. Patients with severe functional class IV heart failure and recent
instability were excluded from CIBIS-II, as in our study.
2149JACC Vol. 34, No. 7, 1999 Letters to the Editor
December 1999:2148–51
Peter Macdonald, FRACP, PHD
Associate Professor of Medicine
Staff Cardiologist
Heart and Lung Transplant Unit
Victoria Street
Darlinghurst
NSW 2010 Australia
PII S0735-1097(99)00481-7
REFERENCES
1. Macdonald PS, Keogh AM, Aboyoun CL, Lund M, Amor R, McCaf-
frey DJ. Tolerability and efficacy of carvedilol in patients with New York
Heart Association class IV heart failure. J Am Coll Cardiol 1999;33:
924–31.
2. The Cardiac Insufficiency Bisoprolol Study II (CIBIS-II): a randomised
trial. Lancet 1999;353:9–13.
Winter and Cardiovascular Mortality
I read with interest the report by Sheth et al. (1) on seasonal variations
of coronary heart disease and stroke mortality, and I would like to
present a new analysis of data culled from an old Brazilian study
performed in Sa˜o Paulo, a city situated at the Tropic of Capricorn.
Between January 1932 and December 1941, Chiaverini and Rey
(2) studied all deaths from congestive heart failure (CHF) con-
firmed by the city’s unique autopsy service. They concluded that
most of the CHF deaths occurred during the winter, which in Sa˜o
Paulo runs from June to August. I examined the mortality data
during a shorter period (July 1939 to December 1941), because
there was better weather data, and confirmed Chiaverini and Rey’s
results. In my analysis, CHF deaths were 28.8% higher during the
winter months as compared with the summer months (December
to February). Minimal monthly temperature (annual range 7.7 to
18.1°C) had a persistent association with CHF deaths (r 5 20.31,
p 5 0.0456) after multiple linear regression analysis for humidity,
hours of sunlight, temperature range and CHF mortality. These
results from historic data are in concordance with a recent report
analyzing coronary artery disease mortality in Hawaii (3), which is
located at an equivalent latitude as Sa˜o Paulo, but in the Northern
Hemisphere. However, the most relevant finding from Chiaverini and
Rey’s study is that most of the CHF cases were categorized as
“nonatherosclerotic diseases.” During the 1940s in Sa˜o Paulo (4), the
etiology of CHF was rheumatic (23.6%), hypertensive heart disease
(23.1%), atherosclerosis (20.6%), Chagas’ disease (10.8%) and syphilis
(7.1%). Given these data, it is plausible to speculate that seasonal
variations in cardiovascular mortality may be due to factors directly
associated with impairment of myocardial contractility, such as ar-
rhythmias and increasing blood pressure, rather than to factors more
specifically related to rupture of coronary atherosclerotic plaque.
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Dynamic Left Ventricular Outflow
Tract Obstruction as a Potential
Mechanism of Myocardial Rupture
After Acute Myocardial Infarction
We read with great interest the study of Becker et al. (1), who
investigated the incidence and predictive factors of fatal cardiac
rupture in patients treated with thrombolysis enrolled in the
Thrombolysis and Thrombin Inhibition in Myocardial Infarction
(TIMI-9) study. The authors reported female gender and age as
independent risk factors for fatal cardiac rupture. Of note, they did
not observe a significant relation between anticoagulation therapy
and cardiac rupture. In contrast, the incidence of rupture was
higher in patients with anterior myocardial infarction not receiving
early angiotensin-converting enzyme inhibition and beta-blockers.
Although the study did not address directly pathophysiologic
mechanisms of the rupture, the authors speculated that changes in
collagen matrix associated with aging and, potentially, with female
gender may underlie the higher risk for mortality. This sounds
plausible, but nevertheless, the authors do not report some clini-
cally relevant information such as the extent of coronary artery
disease and overall or regional left ventricular (LV) function.
Likewise, they do not address triggers that may precipitate the
occurrence of the rupture. However, Oliva et al. (2) reported that
myocardial rupture is often preceded by particular signs—namely
emesis, restlessness, pericarditis, alterations of the T waves and
abrupt episodes of bradycardia or hypotension. The latter signs
deserve closer attention by clinicians. Hypotension or bradycardia
is often present owing to the activation of LV mechanoreceptors in
patients with LV outflow tract (LVOT) obstruction. We have
recently reported a novel observation of a dynamic LVOT obstruc-
tion with systolic anterior motion of the mitral leaflets in patients
after acute anterior myocardial infarction that preceded a cardiac
rupture or intraventricular septal defect (3). The LVOT obstruc-
tion was observed in women with nonhypertrophied ventricles and
calcified posterior mitral annulus and/or thickened mitral leaflets
who presented with hyperdynamic contraction of the noninfarct-
related artery segments. Since this publication (3), we observed a
third myocardial rupture also preceded by LVOT obstruction in a
57-year-old man. Based on our observations, we postulated that
the presence of the LVOT obstruction led to an increase in the
end-systolic wall stress of the infarct segments, which may repre-
sent a direct mechanical insult to a weakened necrotic tissue. This
observation has several potential clinical implications. First, it
implies that in patients with a large anterior infarction and
hyperkinetic noninfarct segments, particular attention should be
paid to LVOT flow dynamics, especially in women with abnor-
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